Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
The objective of this study was to investigate the single-dose relative bioavailability of Mylan\'s oxybutynin chloride extended-release tablets to ALZA\'s Ditropan XL® tablets following an oral, single 20 mg (2 x 10 mg) dose under fasting conditions.
Epistemonikos ID: 388d624b9f227e24144f576c016f2cf4cccfa2de
First added on: May 04, 2024